HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Scott David Lee Selected Research

Aftercare (After-Treatment)

1/2022Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn's Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Scott David Lee Research Topics

Disease

4Crohn Disease (Crohn's Disease)
04/2022 - 01/2019
1Pyoderma Gangrenosum
01/2022
1Necrosis
01/2019
1Neoplasms (Cancer)
01/2019

Drug/Important Bio-Agent (IBA)

2tofacitinibIBA
01/2022 - 01/2022
1Ustekinumab (CNTO 1275)FDA Link
04/2022
1Capsules (Microcapsules)IBA
01/2022
1Phenobarbital (Luminal)FDA Link
01/2022
1Tumor Necrosis Factor InhibitorsIBA
01/2019
1Certolizumab PegolFDA Link
01/2019
1Infliximab (Remicade)FDA Link
01/2019
1Adrenal Cortex Hormones (Corticosteroids)IBA
01/2019
1golimumabFDA Link
01/2019
1AlbuminsIBA
01/2019

Therapy/Procedure

3Therapeutics
01/2022 - 01/2019
2Biological Therapy
01/2022 - 01/2019
1Aftercare (After-Treatment)
01/2022